CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析*

doi:10.3969/j.issn.1672-5069.2024.02.030

摘要/Abstract

摘要： 目的研究CT与磁共振(MRI)增强扫描诊断肝血管瘤(HH)和肝细胞癌(HCC)的价值。方法 2020年6月～2022年6月淮安市第一人民医院诊治的HH患者32例和HCC患者37例, 常规接受CT和MRI增强扫描, 经手术或穿刺取得肝组织, 行病理学检查。采用Kappa检验评定诊断方法之间的一致性, 应用MedCalc1 5.1统计学软件绘制受试者工作特征曲线(ROC), 计算曲线下面积(AUC), 评估诊断效能。结果以病理学检查为诊断的金标准, CT增强扫描发现29例(78.4%)HCC和24例(75.0%)HH, 而MRI扫描发现35例(94.6%)HCC和29例(90.6%)HH;经Kappa一致性检验, CT和MRI扫描与病理学诊断HH和HCC具有一致性(Kappa=0.532, P<0.05和Kappa=0.749, P<0.05); MRI扫描诊断肝内占位性的灵敏度、特异度和准确性分别94.6%、90.6%和92.8%, 显著优于CT诊断(分别为78.4%、75.0%和76.8%, 而两者联合诊断并不能显著提高诊断效能(分别为90.6%、90.6%和92.8%)。结论临床在鉴别原发性肝癌与HH困难时, 应首先进行MRI检查。

关键词: 肝细胞癌, 肝血管瘤, CT扫描, 磁共振成像, 诊断

Abstract: Objective The aim of this study was to compare the diagnostic efficacy of CT and magnetic resonance imaging (MRI) in the differential diagnosis of patients with hepatic hemangioma (HH) and hepatocellular carcinoma (HCC). Methods 69 patients with intrahepatic space-occupying lesions were encountered in Huai 'an First People's Hospital between June 2020 and June 2022, all patients received enhanced CT and MRI scanning, and underwent liver biopsies or hepatectomy. The Kappa test was used to analyze the agreement between CT and MRI diagnosis based on histopathological diagnosis. The area under the receiver operating characteristic curve (AUC) was applied to determine the diagnostic efficacy. Results Based on histopathological examination, the CT scan found primary liver cancer (PLC) in 29 cases (78.4%) and HH in 24 cases(75.0%), while the MRI diagnose correctly PLC in 35 cases (94.6%) and HH in 29 cases; the enhanced CT and MRI scan were consistent with the pathological diagnosis as respect to the diagnosis of HH and HCC by Kappa test (Kappa=0.532, P<0.05 and Kappa=0.749, P<0.05); the sensitivity (Se), the specificity (Sp) and the accuracy by MRI scan in diagnosing the intrahepatic occupying lesions were 94.6%, 90.6% and 92.8%, much superior to 78.4%, 75.0% and 76.8% by CT scan, while the combination of the two didn’t improve the diagnostic efficacy (90.6%, 90.6% and 92.8%, respectively). Conclusion The optimal check-up might be the MRI scan in determining the quality of intrahepatic occupying lesions.

Key words: Hepatocellular carcinoma, Hepatic hemangioma, Enhanced CT scan, Magnetic resonance imaging, Diagnosis

魏野, 汪施妤, 葛高华, 井桂银. CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 279-282.

Wei Ye, Wang Shiyu, Ge Gaohua, et al.. Is the magnetic resonance imaging superior to CT scan in the differential diagnosis of hepatic hemangioma and hepatocellular carcinoma?[J]. Journal of Practical Hepatology, 2024, 27(2): 279-282.

参考文献

[1] Ren Z, Ma X, Duan Z, et al. Diagnosis, therapy, and prognosis for hepatocellular carcinoma. Anal Cell Pathol (Amst), 2020,2(3):8157406.
[2] Kou K, Chen YG, Zhou JP, et al. Hepatic epithelioid hemangioendothelioma: update on diagnosis and therapy. World J Clin Cases, 2020,8(18):3978-3987.
[3] Cohen O, Aleem M, Wolberink S, et al. Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma. BMJ Case Rep, 2021,14(9):e242625.
[4] 王晶,张洁,赵静. 超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究. 实用肝脏病杂志,2022,25(4):575-578.
[5] Selvaraj EA, Mozes FE, Jayaswal A, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol, 2021,75(4):770-785.
[6] Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med, 2021,62(6):779-786.
[7] 国际肝胆胰协会中国分会肝血管瘤专业委员会. 肝血管瘤诊断和治疗多学科专家共识(2019版). 临床肝胆病杂志,2019,35(9):1928-1932.
[8] 中国抗癌协会肝癌专业委员会(CSLC),中国抗癌协会临床肿瘤学协作专业委员会(CSCO),中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识.肝脏,2009,14(3):237-245.
[9] Ghafar J, Ahmad Z. Hepatic epithelioid hemangioendothelioma: case series of a rare vascular tumor mimicking metastases. Diagn Pathol, 2020,15(1):120.
[10] Kanno H, Sato T, Midorikawa R, et al. Hepatic epithelioid hemangioendothelioma presenting synchronously with hepatocellular carcinoma. Case Rep Gastroenterol, 2021,15(1):344-351.
[11] Li W, Li R, Zhao X, et al. Differentiation of hepatocellular carcinoma from hepatic hemangioma and focal nodular hyperplasia using computed tomographic spectral imaging. J Clin Transl Hepatol, 2021,9(3):315-323.
[12] 胡菁,夏茂鑫,任艳. 超声及CT鉴别诊断肝硬化背景下肝血管瘤、肝细胞肝癌的临床价值探讨. 中国CT和MRI杂志,2020,18(8):80-82.
[13] Kim YY, Kang TW, Cha DI, et al. Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. Eur J Radiol, 2021,13(135):109474.
[14] Cao Y, Yu J, Zhang H, et al. Classification of hepatic cavernous hemangioma or hepatocellular carcinoma using a convolutional neural network model. J Gastrointest Oncol, 2022,13(2):787-791.
[15] Yoon J, Park SH, Ahn SJ, et al. Atypical manifestation of primary hepatocellular carcinoma and hepatic malignancy mimicking lesions. J Korean Soc Radiol, 2022,83(4):808-829.
[16] 代小兵,刘启榆,吴俊辉. 磁共振增强扫描弥散加权成像对肝脏良恶性肿瘤的鉴别诊断价值研究. 实用肝脏病杂志,2021,24(2):268-271.
[17] Jia C, Liu G, Wang X, et al. Hepatic sclerosed hemangioma and sclerosing cavernous hemangioma: a radiological study. Jpn J Radiol, 2021,39(11):1059-1068.
[18] Dane B, Shanbhogue K, Menias CO, et al. The humbling hemangioma: uncommon CT and MRI imaging features and mimickers of hepatic hemangiomas. Clin Imaging, 2021,9(74):55-63.
[19] Nasher O, Woodley H, Alizai S, et al. Hepatic benign and malignant masses in children: a single UK tertiary centre experience. Pediatr Surg Int, 2022,38(12):2019-2022.
[20] Wu J, Liu A, Cui J, et al. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images. BMC Med Imaging, 2019,19(1):23.

CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析^*

Is the magnetic resonance imaging superior to CT scan in the differential diagnosis of hepatic hemangioma and hepatocellular carcinoma?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	高明慧, 柴梦音, 寇卜心, 豆双双, 刘晓霓. ASPP2重组腺病毒通过调控NF-κB信号通路抑制DEN诱导的小鼠肝细胞癌发生^*[J]. 实用肝脏病杂志, 2024, 27(2): 169-172.
[3]	郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 189-192.
[4]	李敏, 张丽, 曾艾, 刘世裕. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 193-197.
[5]	郑波, 哈丽达·夏尔甫哈孜, 谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 198-201.
[6]	童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 202-205.
[7]	朱春芬, 任春霖, 郭霞. 血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 242-245.
[8]	冯彦菲, 苏明华, 殷倩冰, 黎清梅, 苏土梅, 梁蘅恺, 韦璐, 黄建芳, 江建宁. 一组非肝硬化性门静脉高压症病因分析和诊断路径探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 246-250.
[9]	哈鹏, 苏晓晨, 付宾鹏. 三期增强CT扫描联合血清AFP和VEGF水平诊断肝细胞癌患者临床研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 251-254.
[10]	谢晶美, 刘浩, 李安, 李华, 陈苗苗, 郭宝琴, 石洋洋, 朱志敏, 郭晨光. 动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 255-258.
[11]	张亚龙, 胡冬梅, 赵晟, 孟海生. 超声引导下射频消融治疗小原发性肝癌疗效及死亡危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 271-274.
[12]	崔甜甜, 张海波, 陈莉莉. 能谱CT增强扫描参数鉴别诊断肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 275-278.
[13]	贾江坤, 余淼, 贾萌, 徐健, 王佳佳, 宋红霞, 申权, 薛焕洲, 陈旭晓. 腹腔镜辅助下血管瘤剥除术与解剖性肝切除术治疗巨大肝血管瘤疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(2): 287-290.
[14]	贾永利, 王鹏川, 郭伟, 孙东莹. 低频与高频超声联合诊断胆囊息肉样病变价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 307-310.
[15]	章正威, 夏德鑫, 朱宝林, 章应峰, 王翔, 张彤. 早期原发性胆囊癌增强磁共振和CT扫描征象分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 311-313.